WASHINGTON — Less than six months ago, President Trump stood at a podium and roiled the pharmaceutical industry with an emphatic declaration that its executives are “getting away with murder.”
If Congress has its way, the same president will soon sign into law a massive package that is at the top of the industry’s wish list: a reauthorization of drug makers’ funding agreements with the Food and Drug Administration.
At least so far, the powerful pharmaceutical industry has managed to keep the package that is speeding toward Trump’s desk free of any controversial policy changes that could threaten the industry’s business model — as well as any partisan add-ons that could jeopardize its smooth, overwhelmingly bipartisan trip through the policymaking process.
My son is a PHD on porting. He is an expat oOn biotechnology & have a post graduate deploma in bio informatics and working 11 years as professor. He desires to work with a good package. Pl.help.
Comments are closed.